A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001)
Head and Neck, vol.45, no.5, pp.1194-1205, 2023 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 45 Issue: 5
- Publication Date: 2023
- Doi Number: 10.1002/hed.27333
- Journal Name: Head and Neck
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Page Numbers: pp.1194-1205
- Keywords: chemoradiotherapy, EBV-DNA, intensity-modulated radiotherapy, nasopharyngeal carcinoma, nonendemic, INTENSITY-MODULATED RADIOTHERAPY, AJCC/UICC STAGING SYSTEM, CONCURRENT CHEMORADIOTHERAPY, 8TH EDITION, CHEMOTHERAPY, DNA, VALIDATION, WORLDWIDE, OUTCOMES, TRIALS
- Open Archive Collection: AVESIS Open Access Collection
- Bursa Uludag University Affiliated: Yes
Abstract
Background: We aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. Methods: In a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. Results: Median age was 48 (9–83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6–78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age ≥50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA). Conclusions: Patients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.